Archive: 01/05/2017
Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial
Serelaxin has failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late breaking results presented for the first time today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure.
May 1, 2017